Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy

Epithelioid glioblastoma is a rare aggressive variant of glioblastoma (GBM) characterized by a dismal prognosis of about 6 months and frequent leptomeningeal dissemination. A recent study has revealed that 50% of epithelioid GBMs harbor three genetic alterations – BRAF V600E mutation, TERT promoter...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanemaru, Yu, Natsumeda, Manabu, Okada, Masayasu, Saito, Rie, Kobayashi, Daiki, Eda, Takeyoshi, Watanabe, Jun, Saito, Shoji, Tsukamoto, Yoshihiro, Oishi, Makoto, Saito, Hirotake, Nagahashi, Masayuki, Sasaki, Takahiro, Hashizume, Rintaro, Aoyama, Hidefumi, Wakai, Toshifumi, Kakita, Akiyoshi, Fujii, Yukihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659204/
https://www.ncbi.nlm.nih.gov/pubmed/31345255
http://dx.doi.org/10.1186/s40478-019-0774-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659204/
https://www.ncbi.nlm.nih.gov/pubmed/31345255
http://dx.doi.org/10.1186/s40478-019-0774-7

Ejemplares similares